Intensive Care Medicine

, Volume 35, Issue 8, pp 1406–1411

‘Liver function tests’ on the intensive care unit: a prospective, observational study

  • S. J. Thomson
  • M. L. Cowan
  • I. Johnston
  • S. Musa
  • M. Grounds
  • T. M. Rahman
Original

Abstract

Aims

To evaluate the prevalence, patterns and significance of deranged liver function tests (LFT) in critically ill patients.

Methods

A prospective, observational data collection of the LFT [bilirubin, alanine aminotransferase (ALT), alkaline phosphatase (AKP), gamma glutaryl transferase (γGT)] and critical care parameters in all admissions to the general intensive care unit (ICU) of our institution. Prevalence of abnormal LFT on the day of ITU admission is described and the relationship of abnormal LFT to clinical events and 30-day mortality analysed.

Results

Of 263 first admissions without hepatobiliary disease, 61% demonstrated an abnormal LFT at the point of admission. The majority of abnormalities were less than twice the upper limit of normal. Episodes of ventilation, haemofiltration and hypotension during the first 48 h were associated with an abnormal ALT on day 3. The presence of an abnormal ALT [odds ratio 2.7 (1.2–6.0)], AKP [OR 2.8 (1.1–7.3)] or γGT [OR 3.9 (1.9–8.3)] was associated with an increased risk of death within 30 days of admission. When adjusted for APACHE II score, LFTs were not independent predictors of mortality.

Discussion

Low-grade abnormalities of LFT are a significant entity in critically ill patients and show an association with mortality outcomes and clinical events on ICU. They are likely to represent part of a spectrum of liver injury associated with critical illness and should not be disregarded.

Keywords

Liver function test Critical care Bilirubin Alanine transaminase Alkaline phosphatase Gamma glutaryl transferase 

References

  1. 1.
    Thomson SJ et al (2008) British Society of Gastroenterology abstracts 2008. Gut 57 Suppl 1:A85Google Scholar
  2. 2.
    Birrer R, Takuda Y, Takara T (2007) Hypoxic hepatopathy: pathophysiology and prognosis. Intern Med 46:1063–1070PubMedCrossRefGoogle Scholar
  3. 3.
    Chand N, Sanyal AJ (2007) Sepsis-induced cholestasis. Hepatology 45:230–241PubMedCrossRefGoogle Scholar
  4. 4.
    Lee WM (2003) Drug-induced hepatotoxicity. N Engl J Med 349:474–485PubMedCrossRefGoogle Scholar
  5. 5.
    Brienza N, Dalfino L, Cinnella G, Diele C, Bruno F, Fiore T (2006) Jaundice in critical illness: promoting factors of a concealed reality. Intensive Care Med 32:267–274PubMedCrossRefGoogle Scholar
  6. 6.
    Kramer L, Jordan B, Druml W, Bauer P, Metnitz PG (2007) Incidence and prognosis of early hepatic dysfunction in critically ill patients—a prospective multicenter study. Crit Care Med 35:1099–1104PubMedCrossRefGoogle Scholar
  7. 7.
    Knaus WA, Draper EA, Wagner DP, Zimmerman JE (1985) APACHE II: a severity of disease classification system. Crit Care Med 13:818–829PubMedCrossRefGoogle Scholar
  8. 8.
    Case Mix Programme Database ICNAaRCI, Tavistock House, Tavistock Square, London WC1H 9HR (2008)Google Scholar
  9. 9.
    Seeto RK, Fenn B, Rockey DC (2000) Ischemic hepatitis: clinical presentation and pathogenesis. Am J Med 109:109–113PubMedCrossRefGoogle Scholar
  10. 10.
    Koskinas J, Gomatos IP, Tiniakos DG, Memos N, Boutsikou M, Garatzioti A, Archimandritis A, Betrosian A (2008) Liver histology in ICU patients dying from sepsis: a clinico-pathological study. World J Gastroenterol 14:1389–1393PubMedCrossRefGoogle Scholar
  11. 11.
    Jinks MF, Kelly CA (2004) The pattern and significance of abnormal liver function tests in community-acquired pneumonia. Eur J Intern Med 15:436–440PubMedCrossRefGoogle Scholar
  12. 12.
    Le Gall JR, Lemeshow S, Saulnier F (1993) A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957–2963PubMedCrossRefGoogle Scholar
  13. 13.
    Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22:707–710PubMedCrossRefGoogle Scholar
  14. 14.
    Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I (2004) Normal serum aminotransferase concentration and risk of mortality from liver diseases prospective cohort study. BMJ 328:983PubMedCrossRefGoogle Scholar
  15. 15.
    Ioannou GN, Weiss NS, Boyko EJ, Mozaffarian D, Lee SP (2006) Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology 43:1145–1151PubMedCrossRefGoogle Scholar
  16. 16.
    Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC (2008) Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 47:1363–1370PubMedCrossRefGoogle Scholar
  17. 17.
    Kazemi-Shirazi L, Endler G, Winkler S, Schickbauer T, Wagner O, Marsik C (2007) Gamma glutamyltransferase and long-term survival: is it just the liver? Clin Chem 53:940–946PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • S. J. Thomson
    • 1
    • 2
  • M. L. Cowan
    • 1
  • I. Johnston
    • 1
    • 2
  • S. Musa
    • 1
    • 2
  • M. Grounds
    • 2
  • T. M. Rahman
    • 1
    • 2
  1. 1.Department of Gastroenterology and HepatologySt George’s HospitalLondonUK
  2. 2.Department of Intensive Care MedicineSt George’s HospitalLondonUK

Personalised recommendations